argenex SE $ARGX Shares Purchased by Crossmark Global Holdings Inc.

Crossmark Global Holdings Inc. increased its holdings in shares of argenex SE (NASDAQ:ARGX) by 11.7% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 9,684 shares of the company’s stock after purchasing an additional 1,016 shares during the period. Crossmark Global Holdings Inc.’s holdings in argenex were worth $8,985,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the business. Whipplewood Advisors LLC acquired a new stake in argenex in the first quarter worth about $28,000. Eastern Bank purchased a new stake in shares of argenex during the second quarter worth about $32,000. Sunbelt Securities Inc. purchased a new stake in shares of argenex during the third quarter worth about $36,000. Axiom Investment Management LLC acquired a new position in shares of argenex during the first quarter valued at about $50,000. Finally, WPG Advisers LLC increased its holdings in shares of argenex by 17.8% during the first quarter. WPG Advisers LLC now owns 86 shares of the company’s stock valued at $63,000 after acquiring an additional 13 shares in the last quarter. 60.32% of the stock is owned by institutional investors and hedge funds.

argenex Stock Up 1.3%

argenex stock opened at $876.00 on Thursday. The stock has a 50-day moving average price of $882.24 and a 200 day moving average price of $820.70. The company has a market capitalization of $54.80 billion, a price-to-earnings ratio of 33.64, a price-to-earnings-growth ratio of 1.07 and a beta of 0.46. argenex SE has a 52 week low of $637.04 and a 52 week high of $953.58.

argenex (NASDAQ:ARGX) last issued its quarterly earnings results on Tuesday, July 21st. The company reported $7.32 earnings per share for the quarter, topping the consensus estimate of $5.86 by $1.46. argenex had a net margin of 32.19% and a return on equity of 43.59%. The company had revenue of $1.54 billion for the quarter, compared to the consensus estimate of $1.45 billion. Research analysts anticipate that argenex SE will post 28.77 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently commented on ARGX. HC Wainwright reiterated a “buy” rating and issued a $940.00 target price on shares of argenex in a research note on Thursday, June 25th. Wedbush upped their price target on shares of argenex from $1,000.00 to $1,050.00 and gave the company an “outperform” rating in a research note on Tuesday, July 28th. Bank of America raised their price target on shares of argenex from $1,016.00 to $1,088.00 and gave the stock a “buy” rating in a report on Thursday, July 2nd. Weiss Ratings downgraded shares of argenex from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, July 23rd. Finally, Morgan Stanley boosted their price objective on shares of argenex from $1,170.00 to $1,180.00 and gave the company an “overweight” rating in a report on Wednesday, June 24th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,056.89.

argenex Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.